Key result
In a canine model of pulmonary hypertension and coronary insufficiency, nitroglycerin, prostaglandin E1, and hydralazine elicited severe regional RV dysfunction suggestive of ischemia.
Why the study?
Do vasodilators (nitroglycerin, prostaglandin E1, hydralazine) impair right ventricular performance in a canine model of pulmonary hypertension and coronary insufficiency?
Population
8 open-chest dogs with induced pulmonary hypertension and subsequent right coronary artery stenosis
Design
Preclinical
Authors
Loading...
May provoke undetected RV ischemia with vasodilators in PH and coronary disease; leaves open human relevance.
Do vasodilators (nitroglycerin, prostaglandin E1, hydralazine) impair right ventricular performance in a canine model of pulmonary hypertension and coronary insufficiency?
In a canine model of pulmonary hypertension and coronary insufficiency, pulmonary vasodilator therapy reduced coronary perfusion pressure and caused severe regional right ventricular ischemia, which may go undetected if only global hemodynamics are monitored.
Hans‐Joachim Priebe (1992) studied Pulmonary hypertension and coronary insufficiency (n=8). Nitroglycerin, prostaglandin E1, and hydralazine was evaluated on Global and regional RV performance and coronary hemodynamics. In a canine model of pulmonary hypertension and coronary insufficiency, nitroglycerin, prostaglandin E1, and hydralazine elicited severe regional RV dysfunction suggestive of ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: